Mantle cell lymphoma, J Clin Oncol, vol.34, pp.1256-69, 2016. ,
The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?, Haematologica, vol.101, pp.104-118, 2016. ,
Current approaches to mantle cell lymphoma: diagnosis, prognosis, and therapies, Am Soc Clin Oncol Educ Book, vol.37, pp.512-537, 2017. ,
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma, N Engl J Med, vol.369, pp.507-523, 2013. ,
Bruton tyrosine kinase (BTK) and its role in B-cell malignancy, Int Rev Immunol, vol.31, pp.119-151, 2012. ,
Imbruvica package insert, 2017. ,
Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia, N Engl J Med, vol.330, pp.1488-91, 1994. ,
Unique mutations of Bruton's tyrosine kinase in fourteen unrelated X-linked agammaglobulinemia families, Hum Mol Genet, vol.3, pp.1899-900, 1994. ,
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion, Ther Adv Hematol, vol.6, pp.242-52, 2015. ,
ACP-196) in relapsed chronic lymphocytic leukemia, N Engl J Med, vol.374, pp.323-355, 2016. ,
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation, Leukemia, vol.29, pp.783-87, 2015. ,
ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients, Cancer Res, vol.75, p.2596, 2015. ,
ACP-196): a covalent Bruton tyrosine kinase (BTK) inhibitor with a differentiated selectivity and in vivo potency profile, J Pharmacol Exp Ther, vol.363, pp.240-52, 2017. ,
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J Clin Oncol, vol.32, pp.3059-68, 2014. ,
Revised response criteria for malignant lymphoma, J Clin Oncol, vol.25, pp.579-86, 2007. ,
Optimal two-stage designs for phase II clinical trials, Control Clin Trials, vol.10, pp.1-10, 1989. ,
DOI : 10.1016/0197-2456(89)90015-9
URL : http://linus.nci.nih.gov/techreport/Optimal2-StageDesigns.pdf
Interpreting the significance of changes in health-related quality-of-life scores, J Clin Oncol, vol.16, pp.139-183, 1998. ,
Egress of CD19(+) CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients, Blood, vol.122, pp.2412-2436, 2013. ,
Cell trafficking in chronic lymphocytic leukemia, Open J Hematol, vol.3, issue.1, p.3, 2012. ,
The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia, Haematologica, vol.100, pp.1495-507, 2015. ,
Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia, Blood, vol.110, pp.3316-3341, 2007. ,
Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL, Blood Adv, vol.1, pp.933-979, 2017. ,
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo, Blood, vol.119, pp.1182-89, 2012. ,
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia, Blood, vol.119, pp.2590-94, 2012. ,